久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國MediciNova
MediciNova ，公司是一家公開上市的生物制藥公司，側重于獲取和發展新的，小分子療法，用于治療疾病的未滿足的需要特別關注美國市場。通過戰略聯盟與日本主要的制藥公司， MediciNova擁有權，多元化的投資組合的臨床和臨床前候選產品，每個MediciNova認為有一個良好的特點和不同的治療資料，有吸引力的商業潛力和專利資產的說法有充分的商業范圍。 MediciNova的管道包括6個臨床階段的化合物，用于治療急性加重哮喘，多發性硬化癥，哮喘，間質性膀胱炎，固體腫瘤的癌癥，廣泛性焦慮癥，早產和尿失禁和前兩個階段的化合物，用于治療血栓性疾病。 MediciNova目前的戰略是集中資源，它的兩個優先候選產品，美國明尼蘇達- 221用于治療急性加重哮喘和Mn - 166用于治療多發性硬化癥，要么追求發展獨立的，如果錳- 221 ，或建立戰略合作，以支持進一步發展，如錳166 。 MediciNova將尋求其他產品賺錢候選人鍵值拐點。

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on its two prioritized product candidates, MN-221 for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations and MN-166 for the treatment of multiple sclerosis, and either pursue development independently, in the case of MN-221, or establish a strategic collaboration to support further development in the United States, in the case of MN-166. MediciNova will seek to monetize its other product candidates at key value inflection points. MediciNova’s executive management team has extensive global development, regulatory and commercial experience, and manages its international clinical and manufacturing operations through efficient and cost-effective utilization of contract research organizations. Headquartered in San Diego, California, MediciNova today has approximately 25 employees.
?